|
Orthologous residues
|
|
p53 (human): T55‑p, p53 (mouse): ‑, p53 iso2 (mouse): ‑, p53 (rat): ‑, p53 (rabbit): N54‑p, p53 (monkey): T55‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
bone cancer, lung cancer, non-small cell lung cancer, neuroblastoma
|
|
Relevant cell lines - cell types - tissues:
IMR32 (neural crest), NCI-H1299 (pulmonary), U2OS (bone cell)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
apigenin
|
|
|
|
decrease
|
|
|
siRNA
|
|
TAF1 (human)
|
|
decrease
|
|
|
leptomycin B
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization, molecular association, regulation
|
|
Effect of modification (process):
apoptosis, altered
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
exportin 1 (human)
|
|
Induces
|
intracellular localization
|
|
electrophoretic visualization, co-immunoprecipitation
|
|
|
Comments:
export to cytoplasm
|
